Back to top

moving-average-crossover: Archive

Zacks Equity Research

Strength Seen in Fidus Investment (FDUS): Can Its 5.6% Jump Turn into More Strength?

Fidus Investment (FDUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

FDUSNegative Net Change TSLXNegative Net Change

Zacks Equity Research

Strength Seen in Alvopetro Energy (ALVOF): Can Its 7.4% Jump Turn into More Strength?

Alvopetro Energy (ALVOF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ALVOFPositive Net Change XIFRNegative Net Change

Zacks Equity Research

Strength Seen in Waystar (WAY): Can Its 9.5% Jump Turn into More Strength?

Waystar (WAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

WAYPositive Net Change GRNDNegative Net Change

Zacks Equity Research

EPR Properties (EPR) Recently Broke Out Above the 20-Day Moving Average

Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?

EPRPositive Net Change

Zacks Equity Research

EPR Properties (EPR) Recently Broke Out Above the 50-Day Moving Average

Should investors be excited or worried when a stock crosses above the 50-Day simple moving average?

EPRPositive Net Change

Zacks Equity Research

Strength Seen in Honeywell International (HON): Can Its 3.7% Jump Turn into More Strength?

Honeywell International (HON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

HONNegative Net Change PKXNegative Net Change

Zacks Equity Research

Arcturus Therapeutics (ARCT) Stock Jumps 5.7%: Will It Continue to Soar?

Arcturus Therapeutics (ARCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ARCTNegative Net Change ALKSNegative Net Change